Tweets
GALAXI-1 Study - Guselkumab effective in Crohn's Disease. 309 CD pts (1/2 refractory dz) Rx w/ either PBO, or IV GUS 200 mg, 600 mg, or 1200 mg at weeks 0, 4, and 8; At week 12, all 3 doses had signif. clinical and endoscopic improvements vs PBO https://t.co/ZGAS6W1Rak
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 2 months ago
Phase 2b DBRPCT of Intranodular injections of adalimumab in 140 pts w/ Dupuytrens contracture showed signif reduction nodule size and hardness ((−4·6 vs −2·2; p=0·0002) at 12 months https://t.co/jXMAyeCL5t https://t.co/0PB81M3v5h
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 2 months ago
FDA update on Paxlovid - for use pts need to have:
- COVID test +
- Mild-mod dz @ risk for severe COVID
- High risk comorbidity
- potential interaction w/ statins, OCPs, HIV meds
- Dose adjust (nirmatrelvir) w/ CKD
- Dose 3 tabs bid x 5d
- Watch LFTs
https://t.co/oSqwlKijXq https://t.co/3Yx1C23QSz
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 2 months ago
Study of 13 European registries on durability/effect of interleukin-17 (IL-17) inhibition with secukinumab: among 2,017 PsA on secukinumab, retention rates were 86% and 76% at 6 and 12 mos, with 12 mo remission rate of 11% to 16% https://t.co/03sJBSbUy6
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 2 months ago
Did you miss last night's TNR on RA, improving future therapy?
We've got you covered. Listen to the playback here.
https://t.co/ci6TZOw3VX https://t.co/31gRUaKbQm
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 2 months ago
Good free patient info handout on LUMBAR SPINAL STENOSIS from JAMA https://t.co/0CkSR2gqaT
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 2 months ago
Korean Health Insurance claims data looked at risk of Aortic Regurgitation, Atrial Fib in Axial Spondyloarthritis - 3:1 comparison of normals found axSpA (n 8877) at signif higher risk for aortic regurgitation (HR 2.55) & AF (1.20) https://t.co/BXLDymQDKZ https://t.co/YtUbwmKpkG
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 2 months ago
RUXCOVID phase 3 RCT ruxolitinib (5mg bid x 14d) + plus standard care in 432 hospitalized COVID-19 showed no benefit over placebo in day 29 primary outcomes (death, respiratory failure (invasive ventilation), or ICU care. https://t.co/eyAit2uOLi https://t.co/R9rA1A4dm5
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 2 months ago
Neural networks of high-res quantitative CT (HR-pQCT) scans allowed for 3D imaging of MCP2 to differentiate normals from #RA & #PsA. 932 of 617 ppts correct AuROC for HC 82%, RA 75%, PsA 68%. UA pts read as 86% RA,11% PsA, & 3% HC https://t.co/wSQgllYgug https://t.co/yA6g55SpeC
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 2 months ago
Thanks so much to all who contributed to April's PsA All the Way campaign on RheumNow. You can find all our PsA content at the link below. Did you learn anything new about PsA from our coverage?
https://t.co/Mo7Yf2cu4i https://t.co/LvpuLtF4Mv
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 2 months ago
Retrospective study of 71 adult-onset Still’s disease pts Rx 1st w/ High-dose glucocorticoids shows 41% failed to respond (poor outcome) by week4 w/ WBC as best predictor. If WBC < 13K 60% responded; if ≥13K only 23.5% https://t.co/tMNDgoqP14 https://t.co/xJrIEUU6iK
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 2 months ago
TLR7 signaling impt to SLE as it drives type I IFN & activation of autoreactive B cells. Nature reports missense TLR7 (Y264H) variant from severe lupus induces guanosine & cGMP & causes murine lupus when introduced into mice. https://t.co/mzAWd3Pke8 https://t.co/knwa7fBLxk
Dr. John Cush @RheumNow ( View Tweet )
4 years 2 months ago
